体外肺モデル市場：タイプ別、用途別-2025-2030年の世界予測

体外肺モデル市場は、2023年に5億9,159万米ドルと評価され、2024年には6億8,938万米ドルに達すると予測され、CAGR 16.94%で成長し、2030年には17億7,017万米ドルに達すると予測されています。

市場セグメンテーションは、より広範なバイオ医薬品およびヘルスケア研究業界の中で、ニッチでありながら拡大しているセグメントです。これらのモデルは、ヒトの肺機能を細胞レベルで再現する人工システムであり、創薬、毒性試験、疾患モデリングのための貴重なツールを提供します。試験管内肺モデルの必要性は、製薬調査方法を迅速化し、動物実験への依存を減らし、ヒトの生理学的反応をよりよく模倣することで、研究結果の正確性と適用性を高める可能性から生じています。応用範囲は医薬品開発、個別化医療、安全性薬理学に及び、エンドユーザーは主に製薬会社、研究機関、CROなどです。

市場成長に影響を与える主な要因としては、喘息やCOPDのような呼吸器疾患の有病率の上昇、組織工学の進歩、動物実験に対する倫理的懸念の高まりなどが挙げられます。個別化医療や臓器オンチップ技術のような分野では、3Dバイオプリンティングや高度生体材料のような技術革新に牽引され、人間の肺を忠実にシミュレートする機会が増えています。しかし、特にプロトコルの標準化、高コスト、ヒト肺生理学のあらゆる側面を正確に再現することの限界など、これらのモデルの最適な利用を抑制しかねない課題も残されています。

データ解析の精度を高めるための人工知能とin vitro肺モデルの統合、全身的な洞察を提供する多臓器モデルの開発、in vivo環境をより正確にシミュレートするためのマイクロ流体工学の活用など、革新的な研究分野の開拓が進んでいます。市場は技術革新主導型に傾いており、競合は中程度から高程度で、技術進歩や共同研究による影響が大きいです。新たなビジネスチャンスを生かすため、利害関係者は費用対効果の向上、モデル精度の向上、テクノロジー企業との戦略的パートナーシップの構築に注力し、現行のin vitro技術で達成可能なことの限界を押し広げる必要があります。

市場力学：急速に進化する体外肺モデル市場の主要市場インサイトを公開

体外肺モデル市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 動物実験に代わる倫理的手法への需要の高まり
  • 創薬開発の増加
  • 疾患研究におけるin-viro肺モデルの広範な使用
• 市場抑制要因
  • 体外肺モデルの開発と維持にかかる高コスト
• 市場機会
  • 個別化医療への傾斜
  • 様々な物質の毒性試験への利用
• 市場の課題
  • 体外肺モデルに伴う生理学的複雑性

ポーターの5つの力：体外肺モデル市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：体外肺モデル市場における外部からの影響の把握

外部マクロ環境要因は、体外肺モデル市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析体外肺モデル市場における競合情勢の把握

体外肺モデル市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス体外肺モデル市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、体外肺モデル市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨体外肺モデル市場における成功への道筋を描く

体外肺モデル市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 動物実験に代わる倫理的な方法への需要が高まる
    • 医薬品の発見と開発の増加
    • 疾患調査におけるin-viro肺モデルの広範な利用
  • 抑制要因
    • 体外肺モデルの開発と維持にかかるコストが高い
  • 機会
    • 個別化医療へのアプローチへの傾向
    • 各種物質の毒性試験への利用
  • 課題
    • 体外肺モデルに関連する生理学的複雑さ
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 体外肺モデル市場：タイプ別

• 2Dモデル
• 3Dモデル

第7章 体外肺モデル市場：用途別

• 3Dモデル開発
• 創薬と毒性学
• 生理学的調査
• 幹細胞調査と再生医療

第8章 南北アメリカの体外肺モデル市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の体外肺モデル市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの体外肺モデル市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AlveoliX AG
• Brainlab AG
• Cn Bio Innovations Limited
• Emulate, Inc.
• Epithelix Sarl
• Hologic, Inc.
• Horizon Discovery Group plc
• Insphero AG
• Lonza Group AG
• Mattek Corporation by Bico Group
• McKesson Corporation
• Merck KGaA
• MICA Information Systems, Inc.
• Mimetas B.V.
• PromoCell GmbH
• STEMCELL Technologies Inc.
• Thermo Fisher Scientific Inc
• Tissuse GmbH
• Varian Medical Systems, Inc

LIST OF FIGURES

• FIGURE 1. IN VITRO LUNG MODEL MARKET RESEARCH PROCESS
• FIGURE 2. IN VITRO LUNG MODEL MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. IN VITRO LUNG MODEL MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. IN VITRO LUNG MODEL MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. IN VITRO LUNG MODEL MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. IN VITRO LUNG MODEL MARKET DYNAMICS
• TABLE 7. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D MODELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D MODELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D MODEL DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DRUG DISCOVERY & TOXICOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PHYSIOLOGICAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY STEM CELL RESEARCH & REGENERATIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 19. ARGENTINA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 21. BRAZIL IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 22. CANADA IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. CANADA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. MEXICO IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. MEXICO IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. AUSTRALIA IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. AUSTRALIA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. CHINA IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. CHINA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. INDIA IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. INDIA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. INDONESIA IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. INDONESIA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. JAPAN IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. JAPAN IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. MALAYSIA IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. MALAYSIA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. PHILIPPINES IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. PHILIPPINES IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. SINGAPORE IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. SINGAPORE IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. SOUTH KOREA IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. SOUTH KOREA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. TAIWAN IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. TAIWAN IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. THAILAND IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. THAILAND IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. VIETNAM IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. VIETNAM IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. DENMARK IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. DENMARK IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. EGYPT IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. EGYPT IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. FINLAND IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. FINLAND IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. FRANCE IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. FRANCE IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. GERMANY IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. GERMANY IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. ISRAEL IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. ISRAEL IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. ITALY IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. ITALY IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. NETHERLANDS IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. NETHERLANDS IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. NIGERIA IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. NIGERIA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. NORWAY IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. NORWAY IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. POLAND IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. POLAND IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. QATAR IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. QATAR IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. RUSSIA IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. RUSSIA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. SAUDI ARABIA IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SAUDI ARABIA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. SPAIN IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SPAIN IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. SWEDEN IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. SWEDEN IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. SWITZERLAND IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. SWITZERLAND IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. TURKEY IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. TURKEY IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. UNITED ARAB EMIRATES IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. UNITED ARAB EMIRATES IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. UNITED KINGDOM IN VITRO LUNG MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. UNITED KINGDOM IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. IN VITRO LUNG MODEL MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 102. IN VITRO LUNG MODEL MARKET, FPNV POSITIONING MATRIX, 2023

The In Vitro Lung Model Market was valued at USD 591.59 million in 2023, expected to reach USD 689.38 million in 2024, and is projected to grow at a CAGR of 16.94%, to USD 1,770.17 million by 2030.

The In Vitro Lung Model market represents a niche yet expanding segment within the broader biopharmaceutical and healthcare research industry. These models are engineered systems that replicate human lung function at a cellular level, providing a valuable tool for drug discovery, toxicity testing, and disease modeling. The necessity for in vitro lung models arises from their potential to expedite pharmaceutical research processes, reduce reliance on animal testing, and better mimic human physiological responses, thereby enhancing the accuracy and applicability of research findings. Applications extend across drug development, personalized medicine, and safety pharmacology, with end-users primarily including pharmaceutical companies, research institutions, and CROs.

Key factors influencing market growth include the rising prevalence of respiratory diseases like asthma and COPD, advancements in tissue engineering, and growing ethical concerns over animal testing. There are notable opportunities in segments such as personalized medicine and organ-on-chip technology, driven by innovations like 3D bioprinting and advanced biomaterials that increasingly simulate human lungs with high fidelity. However, challenges remain, particularly in standardization of protocols, high costs, and limitations in accurately replicating all facets of human lung physiology which could restrain optimal use of these models.

Innovative research areas ripe for exploration include the integration of artificial intelligence with in vitro lung models to enhance data analysis accuracy, development of multi-organ models that provide systemic insights, and the utilization of microfluidics to simulate in vivo environments more accurately. The market leans towards being innovation-driven with a moderate-to-high degree of competition, largely influenced by technological advancements and collaborations. To capitalize on emerging opportunities, stakeholders must focus on increasing cost-effectiveness, improving model accuracy, and forging strategic partnerships with technology firms to push the boundaries of what's achievable with current in vitro technologies.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving In Vitro Lung Model Market

The In Vitro Lung Model Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing demand for ethical alternatives to animal testing
  • Increase in drug discovery and development
  • Extensive use of in-viro lung model in disease research
• Market Restraints
  • High cost of development and maintainence of in-vitro lung model
• Market Opportunities
  • Inclination toward personalized medicine approach
  • Utilization for toxicity testing of various substances
• Market Challenges
  • Physiological complexity associated with in-vitro lung model

Porter's Five Forces: A Strategic Tool for Navigating the In Vitro Lung Model Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the In Vitro Lung Model Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the In Vitro Lung Model Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the In Vitro Lung Model Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the In Vitro Lung Model Market

A detailed market share analysis in the In Vitro Lung Model Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the In Vitro Lung Model Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the In Vitro Lung Model Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the In Vitro Lung Model Market

A strategic analysis of the In Vitro Lung Model Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the In Vitro Lung Model Market, highlighting leading vendors and their innovative profiles. These include AlveoliX AG, Brainlab AG, Cn Bio Innovations Limited, Emulate, Inc., Epithelix Sarl, Hologic, Inc., Horizon Discovery Group plc, Insphero AG, Lonza Group AG, Mattek Corporation by Bico Group, McKesson Corporation, Merck KGaA, MICA Information Systems, Inc., Mimetas B.V., PromoCell GmbH, STEMCELL Technologies Inc., Thermo Fisher Scientific Inc, Tissuse GmbH, and Varian Medical Systems, Inc.

Market Segmentation & Coverage

This research report categorizes the In Vitro Lung Model Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across 2D Models and 3D Models.
• Based on Application, market is studied across 3D Model Development, Drug Discovery & Toxicology, Physiological Research, and Stem Cell Research & Regenerative Medicine.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing demand for ethical alternatives to animal testing
    • 5.1.1.2. Increase in drug discovery and development
    • 5.1.1.3. Extensive use of in-viro lung model in disease research
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of development and maintainence of in-vitro lung model
  • 5.1.3. Opportunities
    • 5.1.3.1. Inclination toward personalized medicine approach
    • 5.1.3.2. Utilization for toxicity testing of various substances
  • 5.1.4. Challenges
    • 5.1.4.1. Physiological complexity associated with in-vitro lung model
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. In Vitro Lung Model Market, by Type

• 6.1. Introduction
• 6.2. 2D Models
• 6.3. 3D Models

7. In Vitro Lung Model Market, by Application

• 7.1. Introduction
• 7.2. 3D Model Development
• 7.3. Drug Discovery & Toxicology
• 7.4. Physiological Research
• 7.5. Stem Cell Research & Regenerative Medicine

8. Americas In Vitro Lung Model Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific In Vitro Lung Model Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa In Vitro Lung Model Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AlveoliX AG
• 2. Brainlab AG
• 3. Cn Bio Innovations Limited
• 4. Emulate, Inc.
• 5. Epithelix Sarl
• 6. Hologic, Inc.
• 7. Horizon Discovery Group plc
• 8. Insphero AG
• 9. Lonza Group AG
• 10. Mattek Corporation by Bico Group
• 11. McKesson Corporation
• 12. Merck KGaA
• 13. MICA Information Systems, Inc.
• 14. Mimetas B.V.
• 15. PromoCell GmbH
• 16. STEMCELL Technologies Inc.
• 17. Thermo Fisher Scientific Inc
• 18. Tissuse GmbH
• 19. Varian Medical Systems, Inc